<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03079505</url>
  </required_header>
  <id_info>
    <org_study_id>17095/17</org_study_id>
    <nct_id>NCT03079505</nct_id>
  </id_info>
  <brief_title>Dasatinib Versus Nilotinib for Treatment Naïve Chronic Myeloid Leukemia</brief_title>
  <acronym>DANIN</acronym>
  <official_title>Dasatinib Versus Nilotinib as Upfront Therapy for Treatment Naïve Chronic Myeloid Leukemia Chronic Phase</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hamad Medical Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hamad Medical Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      DANIN study is a randomized, phase 3 clinical trial comparing 'head to head' Nilotinib versus
      Dasatinib as upfront therapy for patient with chronic myeloid leukemia. The efficacy of both
      drugs will be tested by measuring BCR/ABL (BCR-ABL = fusion gene from BCR (breakpoint cluster
      region gene/BCR gene product) and ABL (Abelson proto-oncogene)) using European Leukemia net
      recommendations the study will be conducted in NCCCR (National Center for Cancer Care &amp;
      Research) sample size calculations detailed in the statistic part the clinical hematologist
      will recruit the patients this will include consenting process inclusion and exclusion
      criteria the molecular pathologist will do the molecular testing the clinical research
      coordinator and fellows will do the CRF (Case Report Form) as well as quality of life
      questionnaire and applying the protocol for evaluation of cardiac evaluation Molecular
      monitoring of BCR-ABL1 transcripts to assess treatment response in CML (Chronic Myeloid
      Leukemia).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 3, 2017</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with a Molecular Response Rate (MMR) at 12 Months from the baseline</measure>
    <time_frame>12 Months</time_frame>
    <description>Rate of MMR is defined as &lt;= 0.1% BCR-ABL/ABL ratio by international scale (IS), measured by real-time quantitative polymerase chain reaction (RQ-PCR) which corresponds to a ≥ 3 log reduction of BCR-ABL transcript from standardized baseline. BCR-ABL = fusion gene from BCR (breakpoint cluster region gene/BCR gene product) and ABL (Abelson proto-oncogene)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with a Durable Molecular Response Rate (MMR) from the baseline</measure>
    <time_frame>12 months to 5 years</time_frame>
    <description>Rate of MMR is defined as &lt;= 0.1% BCR-ABL/ABL ratio by international scale (IS), measured by real-time quantitative polymerase chain reaction (RQ-PCR) which corresponds to a ≥ 3 log reduction of BCR-ABL transcript from standardized baseline. BCR-ABL = fusion gene from BCR (breakpoint cluster region gene/BCR gene product) and ABL (Abelson proto-oncogene) Number of patients with a maintained MMR for 5 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with a Reduction in BCR-ABL Transcript Levels in both arms from the baseline</measure>
    <time_frame>5 years</time_frame>
    <description>BCR-ABL ≤ 10% at 3 months BCR-ABL &lt; 1% at 6 months BCR-ABL ≤ 0.1% at 12 months
then MMR or better
BCR-ABL = fusion gene from BCR (breakpoint cluster region gene/BCR gene product) and ABL (Abelson proto-oncogene)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with a Complete Cytogenetic Response (CCyR) in both arms from the baseline</measure>
    <time_frame>5 years</time_frame>
    <description>Cytogenetic response (CyR) is based on the prevalence of Philadelphia positive (Ph+) cells in metaphase from bone marrow (BM) sample. (Ideally, 25 metaphases but at least 20 metaphases from a BM sample were evaluated). Complete Cytogenetic Response (CCyR)=0% Ph+ cells in metaphase in BM. A cCCyR=those in which all measurements up to at least 28 days after the initial response show an equivalent or better CCyR (Complete Cytogenetic Response).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Chronic Myeloid Leukemia - Chronic Phase</condition>
  <arm_group>
    <arm_group_label>Dasatinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dasatinib 100mg, once daily (QD), will be given to 25 patients, orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nilotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nilotinib 300mg, twice daily (BID), will be given to 25 patients, orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib 100 MG [Sprycel]</intervention_name>
    <description>Dasatinib (Sprycel) 100 milligram, once-daily (QD) will be given to 25 patients orally</description>
    <arm_group_label>Nilotinib</arm_group_label>
    <other_name>Sprycel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nilotinib 150mg oral capsule [Tasigna]</intervention_name>
    <description>Nilotinib (Tasigna) 300 milligram, twice-daily (BID) will be given to 25 patients orally</description>
    <arm_group_label>Dasatinib</arm_group_label>
    <other_name>Tasigna</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients 18 years or over.

          2. Patients must have all of the following:

               -  be enrolled within 3 months of initial diagnosis of CML-CP (Chronic Phase) (date
                  of initial diagnosis is the date of first cytogenetic analysis)

               -  cytogenetic confirmation of the Philadelphia chromosome or variants of (9;22)
                  translocations

               -  patients may have secondary chromosomal abnormalities in addition to the
                  Philadelphia chromosome.

               -  &lt; 15% blasts in peripheral blood and bone marrow;

               -  &lt; 30% blasts plus promyelocytes in peripheral blood and bone marrow;

               -  &lt; 20% basophils in peripheral blood,

               -  100 x 109/L platelets or greater

               -  no evidence of extramedullary leukaemic involvement, with the exception of the
                  hepatosplenomegaly.

          3. Written voluntary informed consent.

        Exclusion Criteria:

        1 - Patients with Ph-negative, BCR-ABL-positive, disease are NOT eligible for the study.

        2. Any prior treatment for CML with: any tyrosine kinase inhibitor (eg imatinib,
        dasatinib); busulphan; interferon-alpha; homoharringtonine; cytosine arabinoside; any other
        investigational agents (hydroxycarbamide and anagrelide are the only drugs permitted).
        Patients will be ineligible for the study if they have received any prior therapy with
        interferon-alpha or imatinib. No exceptions.

        3. Patients who received prior chemotherapy, including regimens used in peripheral blood
        progenitor cells (PBPCs) mobilisation for haematopoietic progenitor-cell transplantation.
        (It is allowable to collect unmobilised PBPCs at diagnosis.) 4. Patient who have had any
        form of prior haemopoietic stem cell transplant, either autograft or allograft.

        5. Patients with an ECOG (Eastern Cooperative Oncology Group) Performance Status Score of 2
        or less.

        6. Patients with serum bilirubin, AST (aspartate aminotransferase), ALT (alanine
        aminotransferase), or creatinine concentrations &gt; 2.0 x the institutional upper limit of
        the normal range (IULN).

        7. Patients with International normalized ratio (INR) or partial thromboplastin time (PTT)
        &gt; 1.5 x IULN, with the exception of patients on treatment with oral anticoagulants.

        8. Patients with uncontrolled medical disease such as diabetes mellitus, thyroid
        dysfunction, neuropsychiatric disorders, infection, angina, or Grade 3/4 cardiac problems
        as defined by the New York Heart Association Criteria.

        9. Patients with known positivity for human immunodeficiency virus (HIV); baseline testing
        for HIV is not required.

        10. Patients who have undergone major surgery within 4 weeks of Study Day 1, or who have
        not recovered from prior major surgery.

        11. Patients who are:

          -  pregnant,

          -  breast feeding,

          -  of childbearing potential without a negative pregnancy test prior to Study Day 1, and

          -  male or female of childbearing potential unwilling to use barrier contraceptive
             precautions throughout the trial (postmenopausal women must be amenorrheic for at
             least 12 months to be considered of non-childbearing potential).

             12. Patients with a history of another malignancy either currently or within the past
             five years, with the exception of basal cell skin carcinoma or cervical carcinoma in
             situ.

             13. Patients with a history of non-compliance to medical regimens or who are
             considered potentially unreliable
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed A Yassin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hamad Medical Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohamed A Yassin</last_name>
    <phone>0097455037393</phone>
    <email>yassin@hamad.qa</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Abdulqadir Nashwan</last_name>
    <phone>0097466473549</phone>
    <email>anashwan@hamad.qa</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Center for Cancer Care &amp; Research (NCCCR)</name>
      <address>
        <city>Doha</city>
        <zip>3050</zip>
        <country>Qatar</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed Yassin</last_name>
    </contact>
    <contact_backup>
      <last_name>Abdulqadir Nashwan</last_name>
      <phone>0097466473549</phone>
      <email>anashwan@hamad.qa</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Qatar</country>
  </location_countries>
  <reference>
    <citation>Goldman JM, Melo JV. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001 Apr 5;344(14):1084-6.</citation>
    <PMID>11287980</PMID>
  </reference>
  <reference>
    <citation>Hehlmann R, Saussele S. Treatment of chronic myeloid leukemia in blast crisis. Haematologica. 2008 Dec;93(12):1765-9. doi: 10.3324/haematol.2008.001214. Review.</citation>
    <PMID>19050065</PMID>
  </reference>
  <reference>
    <citation>Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA; IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006 Dec 7;355(23):2408-17.</citation>
    <PMID>17151364</PMID>
  </reference>
  <reference>
    <citation>Deininger M, O'Brien SG, Guilhot F, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with imatinib [abstract]. Blood (ASH Annual Meeting Abstracts) 2009;114(22). Abstract 1126.</citation>
  </reference>
  <reference>
    <citation>de Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M, Szydlo R, Olavarria E, Kaeda J, Goldman JM, Marin D. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 2008 Jul 10;26(20):3358-63. doi: 10.1200/JCO.2007.15.8154. Epub 2008 Jun 2.</citation>
    <PMID>18519952</PMID>
  </reference>
  <reference>
    <citation>O'Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, Cowan-Jacob SW, Lee FY, Heinrich MC, Deininger MW, Druker BJ. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005 Jun 1;65(11):4500-5.</citation>
    <PMID>15930265</PMID>
  </reference>
  <reference>
    <citation>Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Goldman JM, Shah NP, Kantarjian H; PACE Investigators. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013 Nov 7;369(19):1783-96. doi: 10.1056/NEJMoa1306494. Epub 2013 Nov 1.</citation>
    <PMID>24180494</PMID>
  </reference>
  <reference>
    <citation>Cortes JE, Jones D, O'Brien S, Jabbour E, Ravandi F, Koller C, Borthakur G, Walker B, Zhao W, Shan J, Kantarjian H. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol. 2010 Jan 20;28(3):398-404. doi: 10.1200/JCO.2009.25.4920. Epub 2009 Dec 14.</citation>
    <PMID>20008620</PMID>
  </reference>
  <reference>
    <citation>Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, Moiraghi B, Shen Z, Mayer J, Pasquini R, Nakamae H, Huguet F, Boqué C, Chuah C, Bleickardt E, Bradley-Garelik MB, Zhu C, Szatrowski T, Shapiro D, Baccarani M. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010 Jun 17;362(24):2260-70. doi: 10.1056/NEJMoa1002315. Epub 2010 Jun 5.</citation>
    <PMID>20525995</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2017</study_first_submitted>
  <study_first_submitted_qc>March 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2017</study_first_posted>
  <last_update_submitted>September 12, 2017</last_update_submitted>
  <last_update_submitted_qc>September 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

